31-Mar-2026
No headlines found.
No press releases found.
No news found.
The Fund is an actively managed exchange-traded fund ( ETF ) that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in (i) securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and (ii) derivatives that have economic characteristics similar to such securities. The Fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The Fund invests in exchange-listed equity securities, including common and preferred stock of U.S. and foreign mid, small and micro-capitalization companies, and in total return swaps intended to provide exposure to such companies.
Advisorshares Psychedelics ETF trades on the ARCA stock market under the symbol PSIL.
As of March 31, 2026, PSIL stock price climbed to $16.90 with 6,976 million shares trading.
PSIL has a market cap of $20.03 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, PSIL traded as high as $22.49 and as low as $7.14.
PSIL has outperformed the market in the last year with a price return of +56.6% while the SPY ETF gained +18.4%. PSIL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning -1.2% and +0.1%, respectively, while the SPY returned -5.1% and -2.5%, respectively.
PSIL support price is $15.51 and resistance is $16.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PSIL shares will trade within this expected range on the day.
